Merck to buy clinical-stage biotech firm Cidara Therapeutics for about $9.2bn
MLex Summary: Pharmaceutical heavyweight Merck intends to pay roughly $9.2 billion to acquire flu antiviral medicine developer Cidara Therapeutics, which has ongoing late-stage US clinical trials and a breakthrough therapy designation...To view the full article, register now.
Already a subscriber? Click here to view full article